Results 261 to 270 of about 8,509,826 (346)

The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo controlled cross over study [PDF]

, 2009
Adam M. Deane, Marianne J. Chapman, Robert Fraser, Carly M. Burgstad, Laura K. Besanko, Michael Horowitz   +5 more
openalex   +1 more source

Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women

Cancer Communications, EarlyView.
Iris Garrido‐Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres‐Ruiz, Anna Ágreda‐Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó‐Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo   +15 more
wiley   +1 more source

Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants: A Systematic Review and Meta-analysis.

JAMA Psychiatry, 2022
Scott AJ, Sharpe L, Quinn V, Colagiuri B.   +3 more
europepmc   +1 more source

A Phase 1C, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DM199 Administered Intravenously with a Polyvinyl Chloride Bag in Adult Healthy Subjects and Adults Recently Taking Angiotensin‐Converting Enzyme Inhibitors

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This small phase 1C, open‐label, single ascending dose study evaluated the safety, tolerability, and pharmacokinetics (PKs) of DM199, a recombinant form of human tissue kallikrein‐1 (KLK1). A small sample size of both healthy subjects and hypertensive adults recently taking angiotensin‐converting enzyme inhibitors was studied. KLK1 has a known
Michael Giuffre, Annette D. Lista, Nick Paulson, Lorianne Masuoka   +3 more
wiley   +1 more source

Correction to "A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score". [PDF]

Clin Transl Sci
europepmc   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Placebo Response in Fragile X-associated Tremor/Ataxia Syndrome. [PDF]

Mov Disord Clin Pract, 2020
Hill EJ, Goetz CG, Stebbins GT, Hagerman R, Ouyang B, Hall DA.   +5 more
europepmc   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

PMC7 THE IMPLICATIONS OF DIFFERING ASSUMPTIONS REGARDING THE BASIS OF PLACEBO RESPONSES ON THE ESTIMATION OF COST-EFFECTIVENESS

, 2006
NS Hawkins
openalex   +1 more source